China SXT Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	28.18	18.1	12.07	17.37	15.52
Cash & Short-Term Investments	28.18	18.1	12.07	17.37	15.52
Cash Growth	55.68%	49.95%	-30.50%	11.88%	16.43%
Accounts Receivable	0.93	1.3	1.31	1.34	3.33
Other Receivables	2.07	0.42	-	-	1.62
Total Trade Receivables	3	1.72	1.31	1.34	4.95
Inventory	0.78	0.83	0.79	0.53	1.02
Other Current Assets	2.55	0.65	0.05	0.28	0.96
Total Current Assets	34.51	21.3	14.23	19.52	22.45
Net Property, Plant & Equipment	0.24	0.36	0.56	1.27	1.59
Other Intangible Assets	0.01	0.01	0.02	0.03	0.04
Other Long-Term Assets	-	-	8.31	8.74	9.46
Total Assets	34.75	21.66	23.13	29.55	33.55
Accounts Payable	0.5	1.16	2.33	6.58	10.18
Accrued Expenses	3.3	2.94	2.77	3.14	3.53
Short-Term Debt	0.36	0.7	2.27	3.32	2.03
Current Portion of Long-Term Debt	-	0.01	0.02	0.01	0.01
Current Portion of Leases	0.07	0.06	0.06	0.06	-
Unearned Revenue	0.1	0.06	0.19	0.17	0.08
Other Current Liabilities	0.02	1.09	1.27	1.22	1.29
Total Current Liabilities	4.35	6.01	8.9	14.5	17.12
Long-Term Debt	0.64	0.1	0.12	0.12	-
Long-Term Leases	0.05	0.12	0.18	0.25	-
Total Long-Term Liabilities	0.7	0.21	0.29	0.37	-
Total Liabilities	5.05	6.22	9.2	14.86	17.12
Common Stock	64.13	44.53	39.67	0.91	0.16
Additional Paid-in Capital	-	-	-	35.59	30.99
Accumulated Other Comprehensive Income	-0.2	-1.08	-1.03	-0.2	0.96
Retained Earnings	-34.22	-28.02	-24.71	-21.61	-15.69
Shareholders' Equity	29.71	15.44	13.93	14.69	16.42
Total Liabilities & Equity	34.75	21.66	23.13	29.55	33.55
Total Debt	1.12	0.98	2.65	3.76	2.05
Net Cash (Debt)	27.05	17.12	9.42	13.61	13.48
Net Cash Growth	58.08%	81.63%	-30.77%	0.99%	1.42%
Net Cash Per Share	39.81	-	-	-	-
Book Value	29.71	15.44	13.93	14.69	16.42
Book Value Per Share	43.71	-	-	-	-
Tangible Book Value	29.7	15.43	13.91	14.66	16.39
Tangible Book Value Per Share	43.70	-	-	-	-

SEC Filings: 10-K · 10-Q